Media, investors, advocacy organizations and others, please contact us here.

Publications IgAN

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy

View
Publications

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

Publications

Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile

Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications FSGS

Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications

Physiologically-based Pharmacokinetic Model of Sparsentan to Evaluate Drug-drug Interaction Potential

View
Publications IgAN

Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden

View
Publications IgAN

Kidney Failure Events, Cardiovascular Disease Events and All-Cause Mortality in Immunoglobulin A Nephropathy Patients in a Real-World Database

View
Publications IgAN

Sparsentan is superior to losartan in the gddY mouse model 1 of IgA nephropathy

View
Publications IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

View
Publications FSGS

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis

View
Publications IgAN

IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study

View
Publications IgAN

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

View